Table 1 Patients’ characteristics
Characteristic | Value in study sample |
|---|---|
Number of patients | 64 |
Male | 54 (84.4%) |
Age (years) | 65.4 ± 14.1 |
Body mass index | 28.5 ± 4.1 |
High blood pressure | 34 (53.1%) |
Coronary heart disease | 12 (18.8%) |
Peripheral arterial disease | 3 (4.7%) |
Stroke | 7 (10.9%) |
Dyslipidaemia | 34 (53.1%) |
Diabetes mellitus | 17 (26.6%) |
Chronic sleep apnoea | 9 (14.1%) |
Psoriasis | 6 (9.4%) |
Ongoing diuretic treatment | 15 (23.4%) |
History of renal stones | 11 (17.2%) |
Familial history of gout | 14 (21.9%) |
eGFR (CKD-EPI/MDRD) | 75.6 ± 25.6 |
CKD 3 or worse (clearance <60 ml/min) | 16 (25.0%) |
Daily alcohol consumption (g) | 14.5 ± 22.7 |
Excessive sweetened beverages | 8 (12.5%) |
Excessive purine-rich foods | 17 (26.6%) |
2015 ACR/EULAR diagnosis score | 12.8 ± 2.4 |
Crystal-proven gout | 11 (17.2%) |
Clinical tophi | 21 (32.8%) |
Gout duration (years) | 12.8 ± 12.3 |
Number of flares per year | 4 ± 6 |
Ongoing urate-lowering therapy (n) | 43 (67.2%) |
Urate-lowering therapy | |
Febuxostat | 17 (39.5%) |
Allopurinol | 24 (55.8%) |
Benzbromarone | 1 (2.3%) |
Probenecid | 1 (2.3%) |
Serum uric acid level (mg/dl) | 7.36 ± 2.55 |